Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-28
2008-11-18
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S237800, C514S238500, C514S318000, C514S331000, C544S129000, C544S163000, C544S165000, C544S336000, C544S295000, C544S357000, C544S399000, C544S400000, C546S197000, C546S201000, C546S230000, C546S231000, C546S234000
Reexamination Certificate
active
07452891
ABSTRACT:
The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
REFERENCES:
patent: 2004/0063779 (2004-04-01), Dollinger et al.
Wolff, Manfred E. Burger's Medicinal Chemistry, 5th Ed. Part 1, pp. 975-977 (1995).
Banker et al. “Modern Pharmaceutics”, 3rd Ed. p. 596 (1996).
Vippagunta et al. Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Chan Tin Yau
Clader John W.
Josien Hubert B.
Palani Anandan
Bernhardt Emily
Kalyanaraman Palaiyur S.
Lee William Y.
Schering Corporation
LandOfFree
MCH antagonists and their use in the treatment of obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MCH antagonists and their use in the treatment of obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCH antagonists and their use in the treatment of obesity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034220